NASDAQ:NAOV - NanoVibronix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.78 -0.44 (-13.66 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$3.22
Today's Range$2.78 - $3.26
52-Week Range$2.50 - $5.00
Volume4,311 shs
Average Volume6,527 shs
Market Capitalization$11.34 million
P/E RatioN/A
Dividend YieldN/A
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Receive NAOV News and Ratings via Email

Sign-up to receive the latest news and ratings for NAOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:NAOV



Sales & Book Value

Annual Sales$320,000.00
Book Value$0.12 per share


Net Income$-4,150,000.00
Net Margins-1,260.12%


Market Cap$11.34 million
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable

NanoVibronix (NASDAQ:NAOV) Frequently Asked Questions

What is NanoVibronix's stock symbol?

NanoVibronix trades on the NASDAQ under the ticker symbol "NAOV."

How were NanoVibronix's earnings last quarter?

NanoVibronix Inc (NASDAQ:NAOV) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $0.05 million for the quarter. NanoVibronix had a negative return on equity of 238.17% and a negative net margin of 1,260.12%. View NanoVibronix's Earnings History.

When is NanoVibronix's next earnings date?

NanoVibronix is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for NanoVibronix.

What is the consensus analysts' recommendation for NanoVibronix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoVibronix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoVibronix.

Has NanoVibronix been receiving favorable news coverage?

Media headlines about NAOV stock have trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NanoVibronix earned a news impact score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of NanoVibronix's key competitors?

What other stocks do shareholders of NanoVibronix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoVibronix investors own include Restoration Robotics (HAIR), Kandi Technologies Group (KNDI), xG Technology (XGTI), Canopy Growth (CGC), T2 Biosystems (TTOO), Veritone (VERI), S&P Global (SPGI), Senseonics (SENS), Australian Vanadium (AVL) and Allena Pharmaceuticals (ALNA).

Who are NanoVibronix's key executives?

NanoVibronix's management team includes the folowing people:
  • Mr. Brian M. Murphy, CEO & Director (Age 62)
  • Dr. William Stern, Pres (Age 77)
  • Mr. Stephen R. Brown CPA, Chief Financial Officer (Age 63)
  • Dr. Harold Jacob, Chief Medical Officer & Director (Age 65)
  • Mr. Amir Rippel, VP of Marketing

Who are NanoVibronix's major shareholders?

NanoVibronix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Kennedy Capital Management Inc. (7.95%).

Which major investors are buying NanoVibronix stock?

NAOV stock was purchased by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc..

How do I buy shares of NanoVibronix?

Shares of NAOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NanoVibronix's stock price today?

One share of NAOV stock can currently be purchased for approximately $2.78.

How big of a company is NanoVibronix?

NanoVibronix has a market capitalization of $11.34 million and generates $320,000.00 in revenue each year. NanoVibronix employs 10 workers across the globe.

What is NanoVibronix's official website?

The official website for NanoVibronix is

How can I contact NanoVibronix?

NanoVibronix's mailing address is 525 Executive Blvd, Elmsford NY, 10523. The company can be reached via phone at 914-233-3004 or via email at [email protected]

MarketBeat Community Rating for NanoVibronix (NASDAQ NAOV)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about NanoVibronix and other stocks. Vote "Outperform" if you believe NAOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel